Lido Advisors
CMMB

Lido Advisors’s Chemomab Therapeutics CMMB Stock Holding History

Lido Advisors’s Portfolio CMMB Stock Details CMMB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$23.2K Buy
+14,341
New +$24.2K ﹤0.01% 2105

Other funds holding CMMB

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
KPWS
Kestra Private Wealth Services Austin, Texas $9.1B AUM 32.09% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $133B AUM 43.5% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
PIP
Philadelphia Investment Partners Voorhees, New Jersey $161M AUM
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lido Advisors's CMMB Position: Q2 2026 in Review

Lido Advisors opened a new position in Chemomab Therapeutics (CMMB) in Q2 2026: 14,341 shares worth $23.2K. The stake represents ﹤0.01% of the portfolio and ranks #2105 among its holdings.

13 funds tracked by Wall St. Rank hold CMMB as of Q2 2026.

  • Lido Advisors held 14,341 shares of Chemomab Therapeutics worth $23.2K as of Q2 2026.
  • Chemomab Therapeutics was a new Lido Advisors position in Q2 2026.
  • Chemomab Therapeutics made up ﹤0.01% of Lido Advisors's portfolio in Q2 2026, its #2105 holding.
  • 13 funds tracked by Wall St. Rank held Chemomab Therapeutics as of Q2 2026.

Based on Lido Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.